Condition: Ovarian Cancer Recurrent · Sponsor: Institute of Cancer Research, United Kingdom
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.
This description comes directly from the study's public registry record.
Jessica Russell · +44 2034376516 · soprano-icrctsu@icr.ac.uk
Laura Moretti · +44 0208 722 4153 · soprano-icrctsu@icr.ac.uk
Always discuss trial participation with your own doctor first.
| St James's University Hospital | Leeds, Leeds, United Kingdom | Recruiting |
| Leicester Royal Infirmary | Leicester, Leicester, United Kingdom | Recruiting |
| The Christie NHS Foundation Trust | Manchester, Manchester, United Kingdom | Recruiting |
| Western General Hospital | Edinburgh, Scotland, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | Sutton, Surrey, United Kingdom | Recruiting |
| University College London Hospitals | London, UK, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05990192